{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:50:38Z","timestamp":1789156238290,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Current genetic screening for predisposition to breast cancer (BC) is limited to BRCA1\/2 exons and intron\/exon boundaries, and limited information exists about the impact of variants in BRCA1\/2 non-coding regions. The majority of alterations identified in these regions remain unclassified, but evidence of the impact of variants in the regulatory regions on cancer risk and response to treatment is emerging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>This project aimed to investigate the prevalence of germline variants in the non-coding regulatory regions of BRCA1\/2 and other BC predisposition genes in patients with triple-negative BC (TNBC) selected for age at cancer diagnosis and\/or family history of cancer. The study also aims to investigate the relationship between these variants and clinical outcomes such as overall survival, disease-free survival (DFS), and response to treatment. We analyzed a Next-Generation Sequencing (NGS) custom panel of promoter regions of 28 genes involved in BC predisposition on 144 patients with TNBC previously tested wild type for coding regions of BRCA1\/2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The NGS analysis identified 635 rare variants in promoter regions of the 28 genes. Among the 144 patients, for 75 with available clinical data, rare germline variants in BRCA2 promoter were statistically significantly related to worse overall survival (OS) (P-value\u2005=\u2005.017). No differences in DFS and OS were found for the other genes. Rare variants in the CDH1 promoter were related to the highest percentage of non-pathological complete response after neoadjuvant chemotherapy (P\u2005=\u2005.0273); MLH1 and PALB2 rare non-coding variants were found to be both related to bilateral BC (P\u2005=\u2005.0146 and P\u2005=\u2005.0005, respectively) and ATM promoter variants were associated with a positive family history (P\u2005=\u2005.041).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our results underscore the importance of searching for rare germline variants in regulatory regions of cancer predisposition genes in patients with TNBC, since these variants can be associated with an increased cancer risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf052","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:49:34Z","timestamp":1746712174000},"source":"Crossref","is-referenced-by-count":4,"title":["Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants"],"prefix":"10.1093","volume":"30","author":[{"given":"Michela","family":"Palleschi","sequence":"first","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-3875","authenticated-orcid":false,"given":"Alessandra","family":"Virga","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori \u201d, 47014, Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Fonzi","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori \u201d, 47014, Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Science, University of Bologna , Bologna, 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Merloni","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Sarti","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Danesi","sequence":"additional","affiliation":[{"name":"Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\" , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Ravegnani","sequence":"additional","affiliation":[{"name":"Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\" , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Sirico","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gianni","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Maltoni","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-8538","authenticated-orcid":false,"given":"Sara","family":"Bravaccini","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Calistri","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Arcangeli","sequence":"additional","affiliation":[{"name":"Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\" , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zampiga","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cangini","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Bandini","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mannozzi","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori \u201d, 47014, Meldola ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Falcini","sequence":"additional","affiliation":[{"name":"Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\" , Meldola, 47014 ,","place":["Italy"]},{"name":"Local Health Authority, Cancer Prevention Unit , Forl\u00ec, 47121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Hematology and Sciences Oncology, Institute of Haematology \u201cL. and A. Ser\u00e0gnoli\u201d, S. Orsola University Hospital , Bologna,\u00a040138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola, 47014 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ulivi","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tedaldi","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d ,\u00a0 Meldola, 47014 ,\u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2025050809492646400_CIT0001","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/bjc.2013.144","article-title":"Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers","volume":"108","author":"Lips","year":"2013","journal-title":"Br J Cancer"},{"key":"2025050809492646400_CIT0002","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/bcr2576","article-title":"Incorporating tumour pathology information into breast cancer risk prediction algorithms","volume":"12","author":"Mavaddat","year":"2010","journal-title":"Breast Cancer Res"},{"key":"2025050809492646400_CIT0003","doi-asserted-by":"publisher","first-page":"7884","DOI":"10.3390\/ijms22157884","article-title":"Moving beyond PARP Inhibition: current state and future perspectives in breast cancer","volume":"22","author":"Palleschi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025050809492646400_CIT0004","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.breast.2022.08.012","article-title":"A systematic review and meta-analysis of BRCA1\/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer","volume":"66","author":"Jia","year":"2022","journal-title":"Breast"},{"key":"2025050809492646400_CIT0005","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/jcm12041588","article-title":"Efficacy of PARP inhibitor, platinum, and immunotherapy in BRCA-mutated HER2-negative breast cancer patients: a systematic review and network meta-analysis","volume":"12","author":"Sun","year":"2023","journal-title":"J Clin Med"},{"key":"2025050809492646400_CIT0006","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes\u2014providing evidence of cancer predisposition genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025050809492646400_CIT0007","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.tig.2020.07.004","article-title":"The role of noncoding variants in heritable disease","volume":"36","author":"French","year":"2020","journal-title":"Trends Genet"},{"key":"2025050809492646400_CIT0008","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/cancers10110453","article-title":"Non-coding variants in BRCA1 and BRCA2 genes: potential impact on breast and ovarian cancer predisposition","volume":"10","author":"Santana Dos Santos","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025050809492646400_CIT0009","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/humu.23652","article-title":"BRCA1 and BRCA2 5\u2019 noncoding region variants identified in breast cancer patients alter promoter activity and protein binding","volume":"39","author":"Burke","year":"2018","journal-title":"Hum Mutat"},{"key":"2025050809492646400_CIT0010","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/nsmb.1941","article-title":"Transcriptional regulation of BRCA1 expression by a metabolic switch","volume":"17","author":"Di","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"2025050809492646400_CIT0011","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.synbio.2023.08.006","article-title":"Mechanisms and biotechnological applications of transcription factors","volume":"8","author":"He","year":"2023","journal-title":"Synth Syst Biotechnol"},{"key":"2025050809492646400_CIT0012","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.molmed.2021.07.012","article-title":"Enhancers in disease: molecular basis and emerging treatment strategies","volume":"27","author":"Claringbould","year":"2021","journal-title":"Trends Mol Med."},{"key":"2025050809492646400_CIT0013","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2025050809492646400_CIT0014","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1038\/s41598-023-37698-6","article-title":"Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants","volume":"13","author":"Kang","year":"2023","journal-title":"Sci Rep"},{"key":"2025050809492646400_CIT0015","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41467-021-27666-x","article-title":"Functional dissection of inherited non-coding variation influencing multiple myeloma risk","volume":"13","author":"Ajore","year":"2022","journal-title":"Nat Commun"},{"key":"2025050809492646400_CIT0016","doi-asserted-by":"publisher","first-page":"4","DOI":"10.31083\/j.fbs1601004","article-title":"Decoding non-coding variants: recent approaches to studying their role in gene regulation and human diseases","volume":"16","author":"Pe\u00f1a-Mart\u00ednez","year":"2024","journal-title":"Front Biosci (Schol Ed)"},{"key":"2025050809492646400_CIT0017","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/humu.20901","article-title":"Prediction and assessment of splicing alterations: implications for clinical testing","volume":"29","author":"Spurdle","year":"2008","journal-title":"Hum Mutat"},{"key":"2025050809492646400_CIT0018","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"key":"2025050809492646400_CIT0019","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","article-title":"Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer","volume":"6","author":"Pohl-Rescigno","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025050809492646400_CIT0020","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","article-title":"Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers","volume":"182","author":"Cragun","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2025050809492646400_CIT0021","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N Engl J Med."},{"key":"2025050809492646400_CIT0022","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","article-title":"Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients","volume":"23","author":"Sun","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025050809492646400_CIT0023","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025050809492646400_CIT0024","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol."},{"key":"2025050809492646400_CIT0025","doi-asserted-by":"publisher","first-page":"CD014805","DOI":"10.1002\/14651858.CD014805.pub2","article-title":"Platinum-based chemotherapy for early triple-negative breast cancer","volume":"9","author":"Mason","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050809492646400_CIT0026","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann Oncol."},{"key":"2025050809492646400_CIT0027","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2407-9-62","article-title":"Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia","volume":"9","author":"Budroni","year":"2009","journal-title":"BMC Cancer"},{"key":"2025050809492646400_CIT0028","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025050809492646400_CIT0029","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"2025050809492646400_CIT0030","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/jmedgenet-2015-103216","article-title":"Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study","volume":"52","author":"Harkness","year":"2015","journal-title":"J Med Genet"},{"key":"2025050809492646400_CIT0031","doi-asserted-by":"publisher","first-page":"PO5","DOI":"10.1158\/1538-7445.sabcs23-po5-25-12","article-title":"Abstract PO5-25-12: CDH1 mutations predict resistance to neoadjuvant taxane therapy","volume":"84","author":"Knappskog","year":"2024","journal-title":"Cancer Res"},{"key":"2025050809492646400_CIT0032","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf052\/63126938\/oyaf052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf052\/63126938\/oyaf052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:49:34Z","timestamp":1746712174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf052\/8126965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf052","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf052"}}